
|Videos|February 13, 2016
Dr. James L. Gulley on Treatment Beyond the Second Line in Bladder Cancer
Author(s)James L. Gulley, MD, PhD
Gulley says there is no standard procedure for the third line setting in bladder cancer, and that most oncologists would either turn to single-agent chemotherapy or to clinical trials.
Advertisement
James L. Gulley, MD, PhD, chief of the Genitourinary Malignancies Branch, director of Medical Oncology Service, National Cancer Institute, discusses treatment beyond the second line in bladder cancer. Gulley says there is no standard procedure for the third line setting in bladder cancer, and that most oncologists would either turn to single-agent chemotherapy or to clinical trials.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































